Ditropan, Kentera (previously oxybutynin nicobrand)(oxybutynin)
Kentera, Oxybutynin, Oxytrol (oxybutynin) is a small molecule pharmaceutical. Oxybutynin was first approved as Ditropan on 1982-01-01. It is used to treat dysuria, neurogenic urinary bladder, and urinary incontinence in the USA. It has been approved in Europe to treat urge urinary incontinence. The pharmaceutical is active against muscarinic acetylcholine receptor M1 and muscarinic acetylcholine receptor M3. In addition, it is known to target muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M2, and muscarinic acetylcholine receptor M5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Oxybutynin, Oxytrol (discontinued: Ditropan, Gelnique, Oxybutynin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Oxybutynin chloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GELNIQUE | AbbVie | N-022204 DISCN | 2009-01-27 | 1 products, RLD |
| DITROPAN | Johnson & Johnson | N-017577 DISCN | 1982-01-01 | 1 products, RLD |
| DITROPAN XL | Johnson & Johnson | N-020897 DISCN | 1998-12-16 | 3 products, RLD |
| DITROPAN | Johnson & Johnson | N-018211 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ditropan | New Drug Application | 2012-02-16 |
| gelnique | New Drug Application | 2009-01-15 |
| oxybutynin | ANDA | 2024-12-03 |
| oxybutynin chloride | ANDA | 2025-02-04 |
| oxytrol | New Drug Application | 2024-05-29 |
| oxytrol for women | New Drug Application | 2024-08-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| neurogenic urinary bladder | HP_0000011 | D001750 | N31 |
| urinary incontinence | — | D014549 | R32 |
| dysuria | EFO_0003901 | D053159 | R30 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
97 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 2 | 2 | 7 | 12 | 7 | 30 |
| Urinary incontinence | D014549 | — | R32 | — | 1 | 6 | 5 | 2 | 14 |
| Enuresis | D004775 | — | R32 | — | 1 | 5 | 3 | 2 | 11 |
| Hyperhidrosis | D006945 | — | — | — | 2 | 2 | 1 | 4 | 9 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 3 | 7 | — | 1 | — | 8 |
| Neurogenic urinary bladder | D001750 | HP_0000011 | N31 | — | 1 | 3 | 3 | — | 7 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | 2 | 6 | — | 1 | — | 7 |
| Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | — | 1 | 3 | 1 | 2 | 7 |
| Apnea | D001049 | — | R06.81 | 1 | 5 | — | 1 | — | 6 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | 1 | — | 1 | 1 | 3 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hot flashes | D019584 | — | — | — | 2 | 3 | — | 1 | 6 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 2 | — | — | 2 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | — | 1 | — | — | 1 |
| Polyneuropathies | D011115 | EFO_0009562 | A69.22 | — | — | 1 | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | — | 1 | — | — | 1 |
| Carcinoma in situ | D002278 | — | D09.9 | — | — | 1 | — | — | 1 |
| Breast carcinoma in situ | D000071960 | — | D05 | — | — | 1 | — | — | 1 |
| Lobular carcinoma | D018275 | EFO_0000570 | — | — | — | 1 | — | — | 1 |
| Ductal carcinoma breast | D018270 | — | — | — | — | 1 | — | — | 1 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | 1 | — | — | 1 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 8 | 1 | — | — | — | 9 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | 2 | — | — | — | 2 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | 1 | 2 |
| Allergic rhinitis | D065631 | — | J30.9 | — | 1 | — | — | — | 1 |
| Rhinitis | D012220 | EFO_0008521 | J31 | — | 1 | — | — | — | 1 |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 1 | — | — | — | 1 |
| Rhinorrhea | D000086722 | — | — | — | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
| Male urogenital diseases | D052801 | — | — | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urologic diseases | D014570 | — | N39.9 | — | — | — | — | 1 | 1 |
| Urinary bladder diseases | D001745 | — | N32.9 | — | — | — | — | 1 | 1 |
| Anterior cruciate ligament injuries | D000070598 | — | — | — | — | — | — | 1 | 1 |
| Rupture | D012421 | — | — | — | — | — | — | 1 | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Nephrolithiasis | D053040 | — | N20.0 | — | — | — | — | 1 | 1 |
| Kidney calculi | D007669 | EFO_0004253 | N20 | — | — | — | — | 1 | 1 |
| Urolithiasis | D052878 | — | N20-N23 | — | — | — | — | 1 | 1 |
| Ureteral calculi | D014514 | — | — | — | — | — | — | 1 | 1 |
| Calculi | D002137 | — | — | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Oxybutynin |
| INN | oxybutynin |
| Description | Oxybutynin is a racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder. It has a role as a muscarinic antagonist, a muscle relaxant, an antispasmodic drug, a parasympatholytic, a calcium channel blocker and a local anaesthetic. It is a tertiary amino compound and a racemate. It contains an esoxybutynin and a (R)-oxybutynin. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 5633-20-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1231 |
| ChEBI ID | 7856 |
| PubChem CID | 4634 |
| DrugBank | DB01062 |
| UNII ID | K9P6MC7092 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Oxybutynin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,311 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,931 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use